FindTrial
Sign In

Research on the Clinical Efficacy and Safety of Hematoporphyrin Monomethyl Ether Photodynamic Therapy for Infantile Port-Wine Stains

Research on the Clinical Efficacy and Safety of Hematoporphyrin Monomethyl Ether Photodynamic Therapy for Infantile Port-Wine Stains

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400092995
Enrollment
Unknown
Registered
2024-11-27
Start date
2024-11-28
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Port-Wine Stains

Interventions

A group:Patients received intravenously hemoporfin (5 mg/kg). A 532-nm LED light was used to irradiate the lesion (power density: 55 J/cm2), lasting for 12 min.
B group:Patients received intravenously hemoporfin (4 mg/kg). A 532-nm LED light was used to irradiate the lesion (power density: 55 J/cm2), lasting for 12 min.

Sponsors

West China Second University Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
8 Months to 1 Years

Inclusion criteria

Inclusion criteria: (1) The legal guardian shall provide a written informed consent form according to the requirements of the region or the Institutional Review Board (IRB). (2) Infants with confirmed port-wine stains, aged = 8 months and less than 12 months. (3) patients did not receive any treatment for port-wine stains.

Exclusion criteria

Exclusion criteria: (1) There are contraindications related to HMME-PDT (Hematoporphyrin Monomethyl Ether Photodynamic Therapy) treatment. (2) There are eczema, skin breaks, and bleeding at the lesion site.

Design outcomes

Primary

MeasureTime frame
color change ;regression area ;—

Countries

China

Contacts

Public ContactHu Fan

West China Second University Hospital, Sichuan University

heracleshu@sina.com+86 136 7812 2589

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026